908 Devices deploys XplorIR for instant gas identification in hazmat emergencies
908 Devices has launched XplorIR, a new device designed for instant gas identification and continuous air monitoring during hazardous material emergencies. This technology aims to assist first responders by quickly assessing airborne substances and comparing them to immediate exposure limits, addressing critical information gaps in hazmat incidents. The company previously deployed similar instruments in drills and is working to improve rapid detection and response in various critical situations.
Number of shareholders of 908 Devices Inc. – NASDAQ:MASS
This article provides the number of shareholders for 908 Devices Inc. (NASDAQ: MASS). It lists the company's stock market information and indicates that the data is provided by ICE Data Services and FactSet Research Systems Inc. The content seems to be a financial data page from TradingView.
908 Devices (MASS) price target increased by 10.00% to 11.22
The price target for 908 Devices (MASS) has been increased by 10.00% to $11.22. This update reflects a positive adjustment in the outlook for the company's stock valuation.
908 Devices (MASS) price target increased by 10.00% to 11.22
The price target for 908 Devices (MASS) has been increased by 10.00% to $11.22. This adjustment reflects an updated valuation for the company's stock.
AWM Investment (MASS) logs 5,000-share sale, still holds 5.1M
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc. (MASS), reported an indirect open-market sale of 5,000 shares of Common Stock at a weighted average price of $8.2514 per share on May 11, 2026. This transaction was filed as a Form 4, indicating a negative sentiment and neutral filing impact. After the sale, AWM-advised entities collectively still hold 5,116,715 shares of 908 Devices Common Stock.
Insider Sell: John Kenneweg Sells Shares of 908 Devices Inc (MAS
John Kenneweg, Senior Vice President of Sales & Product Marketing at 908 Devices Inc, sold 18,255 shares of the company on May 8, 2026, reducing his holdings to 57,784 shares. This transaction is part of a trend over the past year, with 14 insider sells and 3 insider buys. Shares were trading at $8.11, indicating the stock is modestly overvalued compared to its GF Value of $6.72.
Insider Sell: John Kenneweg Sells Shares of 908 Devices Inc (MASS)
John Kenneweg, Senior Vice President of Sales & Product Marketing at 908 Devices Inc, sold 18,255 shares of the company on May 8, 2026. This transaction is part of a trend of insider selling at the company, with 14 sells and 3 buys over the past year. Shares of 908 Devices Inc were trading at $8.11, indicating the stock is modestly overvalued according to its GF Value of $6.72.
908 Devices (MASS) SVP sells 18,255 shares in open-market trade
John Kenneweg, SVP of Sales and Product Marketing at 908 Devices Inc. (MASS), sold 18,255 shares of common stock in an open-market transaction on May 8, 2026, at a weighted average price of $8.11 per share. The sales ranged from $7.99 to $8.20. Following these transactions, Kenneweg directly owns 57,784 shares of the company's common stock, totaling a net sale of approximately $148,048.
908 Devices Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:MASS) 2026-05-08
908 Devices Inc. (MASS) announced its Q1 2026 earnings, reporting an EPS of -$0.07, which beat estimates by $0.07. The company's revenue for the quarter was $13.38M, representing a 13.62% year-over-year increase and beating expectations by $219.25K. This article presents the slide deck published by 908 Devices Inc. in conjunction with their earnings call.
[Form 4] 908 Devices Inc. Insider Trading Activity
AWM Investment Company, Inc., a significant owner of 908 Devices Inc. (MASS), reported open-market sales of 78,209 shares across four transactions between May 6-8, 2026, at prices around $8 per share. These sales reduced AWM's indirect holdings to 5,121,715 shares. The Form 4 filing indicates a negative sentiment and high impact due to the insider selling activity.
908 Devices Inc. (MASS) director sells 20,000 shares in planned trade
Christopher D. Brown, a director at 908 Devices Inc. (MASS), sold 20,000 shares of common stock on May 6, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $7.23 per share, with individual prices ranging from $7.00 to $7.49. Following this transaction, Brown directly holds 925,559 shares in the company.
908 Devices (MASS) Q1 Loss Of US$11.9m Tests Bullish Growth Narrative
908 Devices (MASS) reported a Q1 2026 revenue of US$13.4 million and a basic EPS loss of US$0.32, with net losses totaling US$11.9 million for the quarter and US$35.4 million over the last twelve months. While the company shows an 18.6% revenue growth forecast, which is higher than the broader US market, it is not expected to achieve profitability within the next three years, raising concerns for investors despite a prevailing US$8.06 share price and a consensus analyst target of US$10.00. The stock's P/S of 5.2x suggests investors are paying for growth without current profits, leading to conflicting valuation signals.
908 Devices (MASS) Q1 Loss Of US$11.9m Tests Bullish Growth Narrative
908 Devices (MASS) reported a Q1 2026 revenue of US$13.4 million and a net loss of US$11.9 million, continuing a trend of unprofitability. Despite trailing twelve-month revenue growth of 18.6% to US$57.8 million, the company posted a total loss of US$35.4 million, raising concerns about its path to profitability. Analysts note that valuation signals conflict, with the stock trading at a P/S of 5.2x, higher than the industry average but below peers, and above its DCF fair value estimate.
908 Devices Inc. (MASS) reports Q1 loss, tops revenue estimates
908 Devices Inc. (MASS) announced a wider-than-expected Q1 loss but exceeded revenue estimates. The company reported a GAAP loss of $0.23 per share, which was $0.05 worse than analyst predictions, despite a 14.8% increase in revenue year-over-year to $11.7 million, surpassing expectations by $0.46 million. The upbeat revenue performance suggests underlying strength despite the net loss.
908 Devices Inc. (MASS) reports Q1 loss, tops revenue estimates
908 Devices Inc. (MASS) reported a Q1 loss but exceeded revenue estimates. This suggests mixed financial performance for the company during the quarter.
908 Devices Inc. 1Q 2026: Revenue $13.38M, EPS ($0.32) — 10-Q Summary
908 Devices Inc. reported its first-quarter 2026 results, showing a revenue increase to $13.38 million, up 13.6% year-over-year. However, the company experienced a net loss of ($11.96 million), or ($0.32) per share, compared to a net income in the prior year. Key drivers for the revenue growth included a 26% increase in product revenue and improved gross margins due to a shift towards higher-margin domestic sales.
Earnings call transcript: 908 Devices Q1 2026 sees revenue growth, EPS miss
908 Devices Inc. reported Q1 2026 earnings with a 14% year-over-year revenue growth to $13.4 million, but an EPS of -$0.32 significantly missed the -$0.15 forecast. Despite the EPS miss, the stock rose 7.05% pre-market, driven by revenue performance, strategic acquisitions, and improved gross margins. The company also announced the acquisition of NIRLAB AG, aiming to expand its handheld detection portfolio, enhance recurring revenue, and strengthen its market leadership in narcotics detection.
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
908 Devices Inc. reported a strong start to 2026, with first-quarter revenues of $13.4 million, a 14% increase year-over-year, and improved gross margins. The company also announced the acquisition of NIRLAB AG, which expands its narcotics identification capabilities and recurring revenue opportunities. Concurrently, 908 Devices has raised its full-year 2026 revenue outlook to a range of $67.0 million to $70.0 million.
908 Devices Acquires NIRLAB AG to Expand Narcotics Detection Capabilities
908 Devices Inc. has acquired Switzerland-based NIRLAB AG for $15 million upfront, with potential for an additional $8 million in stock-based consideration. This acquisition integrates NIRLAB's AI-powered, cloud-connected near-infrared spectroscopy technology to enhance 908 Devices' handheld narcotics detection capabilities for law enforcement. The combined offering aims to provide rapid, accurate, and comprehensive drug screening solutions, expanding beyond trace detection to include quantitative analysis and a broader range of substances.
908 Devices Completes NIRLAB Acquisition, Advances Growth Strategy
908 Devices (MASS) has completed its acquisition of NIRLAB SA, a move aimed at expanding its narcotics detection portfolio and increasing recurring software revenue. The company reported a 14% year-over-year revenue growth in Q1 2026, reaching $13.4 million, and subsequently raised its full-year revenue outlook to $67 million–$70 million. This acquisition and robust financial performance underpin 908 Devices' strategy to leverage hardware innovation with recurring services in the chemical analysis market.
908 Devices Acquires NIRLAB for $15 Million Plus Up to $8 Million Earn-Out
908 Devices has acquired NIRLAB Group for an initial $15 million, consisting of cash and shares. An additional earn-out of up to $8 million in share-based payments is possible through December 2027, contingent on revenue milestones. The acquisition aims to expand 908 Devices' spectroscopy portfolio and material identification capabilities.
908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
908 Devices Inc. (Nasdaq: MASS) has acquired NIRLAB AG, a Swiss company specializing in AI-powered, cloud-connected near-infrared (NIR) spectroscopy for narcotics detection. This acquisition expands 908 Devices' portfolio in law enforcement, offering a comprehensive solution for rapid, high-volume screening of illicit drugs, including purity quantification and cannabis analysis. The purchase involves an upfront payment of $15 million, with potential additional payments of up to $8 million based on performance milestones.
[10-Q] 908 Devices Inc. Quarterly Earnings Report
908 Devices Inc. reported Q1 2026 revenue from continuing operations of $13.4 million, an increase from $11.8 million in Q1 2025, primarily due to higher handheld device sales. Despite the revenue growth, the company posted a net loss from continuing operations of $12.0 million for the quarter. The report also detailed the acquisition of NIRLAB for $15.0 million in cash and stock, and the achievement of RedWave acquisition performance targets.
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
908 Devices Inc. reported strong Q1 2026 financial results, with a 14% revenue increase year-over-year and significant margin expansion. The company also announced the acquisition of NIRLAB AG, which expands its narcotics detection capabilities and recurring revenue opportunities. Based on these results, 908 Devices has raised its full-year 2026 revenue outlook to $67.0 million to $70.0 million.
Tax-driven share sale by 908 Devices (MASS) SVP after PSU vest
John Kenneweg, SVP of 908 Devices Inc. (MASS), sold 7,787 shares of common stock at $6.83 per share on May 1, 2026. This "sell to cover" transaction was mandated by the company to satisfy tax withholding obligations following the vesting of 26,042 performance stock units (PSUs) on the same date. Kenneweg now directly holds 76,039 shares of common stock, and the sale was non-discretionary.
908 Devices SVP John Kenneweg sells $53,185 in stock
John Kenneweg, SVP of 908 Devices Inc. (NASDAQ:MASS), sold 7,787 shares of company stock for $53,185 to cover tax withholding obligations associated with vested performance stock units. Concurrently, he acquired 26,042 shares through the vesting of these PSUs. Following these transactions, Kenneweg directly holds 76,039 shares, and the company is preparing for its next earnings report on May 12 after solid Q4 2025 results and a positive analyst outlook from Stifel.
908 Devices SVP John Kenneweg sells $53,185 in stock
John Kenneweg, SVP of Sales & Product Marketing at 908 Devices Inc. (NASDAQ:MASS), sold 7,787 shares of company stock valued at $53,185 on May 1, 2026. This "sell to cover" transaction was mandated to satisfy tax withholding obligations related to the vesting of performance stock units (PSUs), through which Kenneweg also acquired 26,042 shares. The company, valued at $245 million, is preparing for its next earnings report on May 12, and recently reported strong Q4 2025 financial results.
908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will release its first-quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. The company will also host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results, which will be accessible via their website. 908 Devices specializes in portable chemical analysis tools for health, safety, and defense applications.
Earnings Preview: 908 Devices to Report Financial Results Pre-market on May 06
908 Devices (NASDAQ: MASS) is set to report its financial results pre-market on Monday, May 6, according to a recent press release. Analysts are forecasting the company to report earnings of ($0.37) per share for the fiscal quarter, with revenue estimated at $12.39 million. This report will provide an update on the company's financial performance and future outlook.
Press Release: 908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will release its first quarter 2026 financial results on Monday, May 6, 2026, after the market closes. The company will also host a conference call and webcast to discuss these results and provide a business update. A replay of the webcast will be available following the event.
908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will report its first-quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. Following the release, company management will host a conference call and webcast at 8:30 a.m. Eastern Time. The webcast will be accessible through the "Investors" section of the company's website.
908 Devices advises new approaches as drug-laced paper designed to bypass detection
908 Devices is highlighting the growing challenge faced by law enforcement with drug-laced paper, which is designed to evade conventional detection methods including K9 units due to its appearance and lack of odor. The company is urging for new and innovative detection strategies to counter increasingly sophisticated smuggling tactics. 908 Devices plans to showcase advanced spectroscopy solutions for customs enforcement, demonstrating its commitment to addressing these evolving security threats.
[ARS] 908 Devices Inc. SEC Filing
This article reports on an ARS SEC filing by 908 Devices Inc. (MASS) with a neutral sentiment and low impact. The filing was accepted on April 29, 2026, and is available as a PDF document. The article also provides a company overview, recent news, and other SEC filings for 908 Devices Inc.
908 Devices (MASS) SVP awarded 26,042 performance stock units as equity pay
John Kenneweg, SVP of Sales & Product Marketing at 908 Devices Inc. (MASS), was granted 26,042 Performance Stock Units (PSUs) as equity compensation, as reported in a Form 4 filing. The company's compensation committee certified the achievement of required performance metrics on April 28, 2026, and the PSUs are scheduled to vest on May 1, 2026. This award represents a contingent right to receive common stock and is a compensation-related equity award, not an open-market trade.
908 Devices deploys VipIR and MX908 at simulated mass casualty drill
908 Devices participated in a simulated mass casualty drill at the University of New Haven Henry C. Lee Institute of Forensic Science. The company deployed its VipIR and MX908 devices to identify chemicals, aiming to enhance rapid chemical threat detection for law enforcement and first responders. This initiative aligns with 908 Devices' focus on advancing chemical analysis technology for defense and security, as seen in their recent presentations and advocacy for new detection standards.
908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates
908 Devices Inc. (MASS) reported a wider-than-expected loss of $0.48 per share for Q1, missing the Zacks Consensus Estimate of a $0.44 per share loss. The company also underperformed revenue expectations, posting $11.7 million against an anticipated $13.6 million. Despite these misses, the company's Q1 revenue grew by 17.5% year-over-year.
908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates
908 Devices Inc. reported a wider-than-expected loss for Q1 2026 at $0.46 per share, missing the Zacks Consensus Estimate of a $0.44 loss. The company also underperformed on revenue, bringing in $10.6 million against an anticipated $11.7 million. Despite these misses, the company's Q1 revenue did increase by 10.4% year-over-year.
908 Devices (NASDAQ: MASS) files Form 3 for Chief Business & Strategy Officer
908 Devices Inc. (NASDAQ: MASS) has filed a Form 3 for Otitoju Kolawole A., who has been appointed as the Chief Business & Strategy Officer. This initial report of beneficial ownership indicates that there are currently no reportable transactions or holdings for him. The filing serves to disclose his status as an officer and establish an opening inventory of his holdings, which are presently zero.
908 Devices (MASS) awards RSUs and stock options to top executive
908 Devices Inc. (MASS) has granted significant equity compensation to its Chief Business & Strategy Officer, Otitoju Kolawole A. He received 110,193 restricted stock units (RSUs) and a stock option for 146,789 shares. Both awards are subject to multi-year vesting schedules contingent on his continued service with the company.
908 Devices (MASS) Names Kola Otitoju as Chief Business & Strate
908 Devices Inc. (MASS) has appointed Kola Otitoju as its new Chief Business & Strategy Officer, a move aimed at enhancing the company's leadership in product and corporate strategies, business development, and M&A. This appointment comes as the company continues to focus on developing handheld devices for chemical analysis in public health, safety, and defense technology sectors. Despite a strong GF Score and financial strength, the company faces challenges in profitability and has seen net insider selling.
908 Devices Inc. (MASS) announced the appointment of Kola Otitoju as the company's Chief Business and Strategy Officer, effective immediately.
908 Devices Inc. (MASS) has appointed Kola Otitoju as Chief Business and Strategy Officer, effective immediately. Ms. Otitoju will be responsible for global business operations, strategic planning, and driving growth. The company also granted her an incentive equity award in line with Nasdaq Listing Rule 5635(C)(4), reflecting its focus on strategic execution and talent development.
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
908 Devices Inc. has appointed Kola Otitoju as its new Chief Business & Strategy Officer, a role in which he will oversee product and corporate strategy, business development, M&A, and partnership initiatives. Mr. Otitoju brings over 25 years of experience in medical technology and life sciences, and was previously SVP of Strategy & Business Development at Repligen Corporation. The company also announced an inducement grant of restricted stock units and options to Mr. Otitoju under Nasdaq Listing Rule 5635(c)(4).
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
908 Devices Inc. has appointed Kola Otitoju as its Chief Business & Strategy Officer, a new executive position focused on product and corporate strategy, business development, M&A, and partnerships. Mr. Otitoju brings over 25 years of experience in medical technology and life sciences. In connection with his appointment, he received an inducement grant of 110,193 restricted stock units and options to purchase 146,789 shares of common stock.
908 Devices names Kola Otitoju as chief business officer
908 Devices Inc. (NASDAQ:MASS) has appointed Kola Otitoju as Chief Business & Strategy Officer, a new executive role. Otitoju will be responsible for product and corporate strategy, business development, M&A, and partnership initiatives, bringing over 25 years of experience in the medical technology and life sciences sectors. The company's stock has seen a 52% return over the past year, and it reported strong Q4 2025 financial results, with Stifel reiterating a Buy rating.
908 Devices (NASDAQ:MASS) SVP Kevin Mccallion Sells 2,693 Shares
908 Devices (NASDAQ:MASS) SVP Kevin Mccallion sold 2,693 shares of the company's stock on April 10th at an average price of $7.01, totaling $18,877.93. This transaction, executed under a Rule 10b5-1 plan, reduced his holdings by 5.66% to 44,925 shares. The stock traded up 1.7% to $7.32, with the company recently beating quarterly earnings expectations but receiving mixed analyst ratings.
Chemical identification solution featured by 908 Devices at security congress in Vienna
908 Devices is showcasing its chemical identification technology at the World Border Security Congress in Vienna, aiming to demonstrate its utility in field operations for detection tasks. The company has previously highlighted its MX908 device for synthetic drug threats and chemical analysis solutions for defense at other industry events. This presentation in Vienna continues 908 Devices' efforts to emphasize its technology's applications in field detection and response.
908 Devices (NASDAQ: MASS) SVP exercises options, sells 2,693 shares under plan
908 Devices Inc. Senior Vice President Kevin J. McCallion exercised stock options for 2,693 shares at $1.05 per share and subsequently sold the same number of shares for a weighted average price of $7.01. This transaction was conducted under a Rule 10b5-1 trading plan established on December 9, 2025. Following these transactions, McCallion directly holds 44,925 shares, and the underlying option grant is now fully exercised.
Kevin Mccallion Sells 5,420 Shares of 908 Devices (NASDAQ:MASS) Stock
Kevin Mccallion, SVP of 908 Devices (NASDAQ:MASS), sold 5,420 shares of the company's stock on April 9th, 2026, for a total of $38,102.60. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and reduced his stake by 10.77%, leaving him with 44,925 shares. The company recently reported better-than-expected quarterly earnings and revenue, while institutional investors hold a significant portion of its stock.
908 Devices to present new customs enforcement spectroscopy at Vienna World Border Congress
908 Devices will attend the World Border Congress in Vienna, where Jeremy VanAuker will present on transforming customs enforcement through modern spectroscopy. The company recently launched its MX908 device for detecting synthetic drugs and showcased its chemical analysis solutions at FIDAE 2024, demonstrating its commitment to advanced security technologies. This presentation highlights their ongoing efforts to enhance border security and detection capabilities.
908 Devices (NASDAQ:MASS) Director Christopher Brown Sells 17,578 Shares
908 Devices (NASDAQ:MASS) Director Christopher Brown sold 17,578 shares of the company's stock on April 10, for a total of $124,276.46. This transaction reduced his holding by 1.83% to 945,559 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected Q1 earnings, with an EPS of ($0.05) and revenue of $17.38 million.
